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Abstract 
Problem 
Chlamydia trachomatis is a significant worldwide health problem, and the 
often-asymptomatic disease can result in infertility. In order to develop a 
successful vaccine, a complete understanding of the immune response to 
chlamydial infection and development of genital tract pathology is required.  
Method of Study 
We utilised the murine genital model of chlamydial infection. Mice were 
immunized with chlamydial Major Outer Membrane Protein (MOMP), and 
vaginal lavage was assessed for the presence of neutralising antibodies. 
These samples were then pre-incubated with Chlamydia muridarum and 
administered to the vaginal vaults of immune competent female BALB/c mice 
to determine the effect on infection.  
Results  
The administration of C. muridarum in conjunction with neutralizing antibodies 
reduced the numbers of mice infected, but a surprising finding was that this 
accelerated the development of severe oviduct pathology. 
Conclusion 
Antibodies play an under-recognized role in chlamydial infection and 
pathology development, which possibly involves interaction with Th1 
immunity.  
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Introduction 
 
Chlamydia trachomatis infections are a significant worldwide burden on 
healthcare, causing both ocular and genital disease. The true incidence of 
disease is uncertain, due to the highly asymptomatic nature of infections, with 
results of screening studies estimating prevalence between 1.5% and 13.3% 
within young adult populations 1, 2. Untreated infections can become chronic 
over time resulting in infertility, thus we require a better understanding of the 
development of Chlamydia-induced pathology, and a successful vaccine 
needs to be developed for both men and women in order to curb this silent 
epidemic. 
 
A successful vaccine will need to enhance or improve the immunity induced 
by a natural infection. Current literature suggests that the Th1 arm of the 
immune response plays the major role in the clearance of chlamydial genital 
infection (reviewed in 3). Animal models of Chlamydia infection of the female 
genital tract have demonstrated that the development of a Th1 response, 
involving influx of IFN-γ secreting CD4+ T cells, is crucial to resolution 4, which 
is confirmed by the fact that IFN- knockout mice cannot induce protective 
immunity despite high levels of vaginal IgA 5.  
 
Conversely, the role of antibodies in clearance of Chlamydia from the vagina 
appears to be more significant following a secondary challenge 6. B cell 
deficient mice are more susceptible to a secondary genital infection, having a 
greater number of mice re-infected than their wild type controls 6. Mice 
deficient in CD4+T cells and B cells are highly susceptible to chlamydial 
genital challenge, but passive immunization with immune serum or 
monoclonal antibodies to chlamydial major outer membrane protein resulted 
in protection against re-infection 7. Interestingly, mice deficient in B cells also 
demonstrate more significant pathology at day 80 following a primary 
chlamydial infection, suggesting broad-specificity antibodies are required to 
protect against tissue damage 8. However, the role of antibodies in enhancing 
cell-mediated immunity in the clearance of a chlamydial infection is not well 
known. Furthermore, most studies assessing the relative impact of Th1 and 
Th2 immunity in clearance of a chlamydial infection have been performed in 
immune-compromised mice models without the capacity to investigate this 
interaction.  
 
The determinants of pathology in a murine model have been investigated. 
One study suggested that upper tract pathology may be caused by a 
prematurely terminated Th1 response leading to increasing chronic infection, 
or an exaggerated proinflammatory Th1 response resulting in tissue damage 
9. Greater numbers of CD4+ cells were found to infiltrate the oviduct tissue 
compared to cervico-vaginal tissue of infected BALB/c mice, despite having 
the same numbers of Th1 cells, thus the oviduct must recruit more non-Th1 
cells. This study also demonstrated a key inverse relationship between the 
strength of the innate immune response induced in the lower reproductive 
tract, and the ability of chlamydiae to ascend to the upper genital tract 9. 
However, the infectious dose is not related to the degree of inflammatory cell 
infiltration and hydrosalpinx development 10. 
 Experiments in knockout mice have demonstrated an important role of CD28 
and CD80/86 in the development of hydrosalpinx, an indicator of subsequent 
infertility 11. Pathology does not develop in TLR2-deficient mice 12. TLR2 is 
required for MIP-2 and TNF- expression, and subsequently neutrophil 
recruitment to the lungs during a Chlamydia pneumoniae infection 13. Recent 
investigations in knockout mice have also indicated a crucial role of IL-1 in 
both clearance of Chlamydia and immunopathology 14. 
  
The interactions between antibodies and cell-mediated immunity in an 
immune-competent model and the role in protective immunity and pathology 
development are unclear. There were two key aims of this study; 1) to 
measure the antibodies produced following immunization with chlamydial 
Major Outer Membrane Protein (MOMP) co-administered with the adjuvants 
cholera toxin and CpG, and 2) to determine if neutralising vaginal lavage (VL) 
antibodies are able to affect the course of infection in vivo in an immune-
competent model.  
 
Materials and Methods   
 
Animals 
Female BALB/c mice (6-8 weeks) were obtained from the Animal Resources 
Centre (Perth, Australia). Animals received food and water ad libitum. All 
procedures were approved by the Queensland University of Technology 
Animal Research Ethics Committee. 
 
Reagents for immunization and chlamydial challenge 
The transformed Escherichia coli (DH5(pMMM3)) expressing the pMAL-c2 
vector encoding recombinant maltose binding protein-MOMP fusion protein 
was a generous gift from Harlan Caldwell (Rocky Mountain Labs, Hamilton, 
MT, USA). MBP-MOMP was produced as previously described 15. Chlamydia 
muridarum (Weiss; ATCC VR-123, Virginia, USA), formerly the mouse 
pneumonitis biovar of C. trachomatis (MoPn), was grown by inoculation of 
McCoy cell (ATCC CRL-1696, Virginia, USA) monolayers and elementary 
bodies (EBs) isolated as previously described 16. Chlamydia muridarum is a 
suitable murine model for chlamydial genital tract infection in humans 17. 
  
Immunization of mice 
In two separate experiments, groups of five mice were immunized with  
MOMP (100g), or cholera toxin (CT;5g)/CpG(10g), or a combination of 
protein and adjuvants. Negative controls were unimmunized naïve mice, and 
positive controls were mice receiving an initial genital inoculation with 5 x 104 
inclusion forming units (ifu) of C. muridarum. Mice were immunized on Day 0, 
and boosts were administered at Days 7,14 and 35.  Vaginal lavage (VL) 
samples were collected at one week following the final boost by flushing the 
vaginal vault five times with a total volume of 40l of sterile phosphate 
buffered saline. 
 
Quantitation of MOMP-specific antibodies by ELISA  
MOMP-specific IgA and IgG titres were determined for VL samples using 
previously described methods 18. Greiner medium-binding 96-well ELISA 
plates (Greiner Bio-One, FL, USA) were coated with 2g/well recombinant 
MBP-MOMP. VL was serially diluted two-fold from 1/10 to 1/1280 in PBS-
Tween. Primary antibodies, biotin-conjugated anti-IgG and anti-IgA, and the 
secondary antibody Streptavidin-HRP conjugate were all used at a dilution of 
1/1000 (Southern Biotechnology Associates, Birmingham AL, USA). The 
plates were developed using 0.1g/ml Tetramethyl-benzidine (TMB, Sigma-
Aldrich, North Ryde NSW Australia) in phosphate citrate buffer (PCB, Sigma-
Aldrich), then stopped by the addition of 1M sulfuric acid. Absorbance of each 
sample was at 450nm and end-point titre (EPT) was defined as the mean 
dilution at which the absorbance reached that of negative wells (mean PBS 
sample absorbance + 2 SD).  
 
VL neutralization of C. muridarum in vitro 
To examine the Chlamydia-neutralizing capacity of these MOMP-specific 
antibodies, the VL samples were examined by in vitro neutralization assay on 
McCoy cells. C. muridarum (5 x 104ifu) was incubated with a 1/5 dilution of VL 
(containing 10l of sample) for 1h at 37C before addition to McCoy cell 
monolayers in 48-well plates. The plates were then incubated for 4h before 
rinsing the monolayers with PBS and replacing with 500l Dulbecco’s 
Modified Eagle’s Medium (DMEM) supplemented with 5% FCS and 1g/ml 
cycloheximide (Sigma-Aldrich). Infection was stopped 24h post-inoculation. 
Chlamydial inclusions were stained using the Chlamydia Cel LPS staining kit 
(CelLabs, Brookvale NSW, Australia). Percent neutralization was determined 
relative to C. muridarum only control wells.  
 
Statistics 
ELISA and in vitro neutralization data are presented as means and SEM. 
Statistical analyses were performed using GraphPad Prism version 4.0b for 
Windows (GraphPad Software, San Diego CA, USA). Differences between 
treatment groups and naïve mice were examined by unpaired two-tailed t-test, 
with significance determined as p<0.05. 
 
Preparation and intra-vaginal inoculation of antibody-bound EBs 
Groups of five naïve mice were given an injection containing 2.5mg of 
medroxyprogesterone acetate (Depo-Provera, Pfizer, West Ryde NSW, 
Australia) subcutaneously, seven days prior to experimentation. For the 
second aim of this study, the characterized VL samples from the first mouse 
experiment were used. As with the in vitro neutralization assay described 
above, 5 x 104ifu C. muridarum was pre-incubated with a 1/5 dilution of VL 
(containing 10l sample) for 1h at 37C. Recipient mice were anaesthetized 
intraperitoneally using ketamine (Parnell Laboratory, Australia) and xylazine 
(Bayer, Australia), and the antibody-bound EB solutions were then 
administered to the vaginal vaults of these mice. An additional control group 
receiving C. muridarum but no VL was included. Infection was monitored by 
collecting cervico-vaginal swabs (Copan, Murrieta, CA, USA) every three days 
post infection. Swabs were placed in tubes containing 500l SPG and glass 
beads and were stored at -80°C. To monitor infection levels, swabs were 
cultured as described elsewhere 10. The inclusions were visualised by staining 
with rabbit anti-C. trachomatis antibody (Pierce/Progen, Richlands NSW, 
Australia) and Immunopure ABC/DAB Staining Kit (Pierce/Progen, Richlands 
NSW, Australia), as described elsewhere 15. Two separate experiments were 
conducted with 5 mice per group for post-infection sample evaluation, and 
results are tabulated as numbers of mice positive for infection (defined as >10 
inclusions per high power field). 
 
Sacrifice and pathology scoring 
At Day 22 post-infection mice were sacrificed using a lethal injection of 
Sodium pentobarbitone. Gross pathology of the oviducts at sacrifice was 
evaluated in situ. The degree of pathology development was recorded and 
graded as described previously 10. Briefly, absence of oviduct dilation was 
given a score of 0; between 2-3mm dilation was given a score of 1 (mild); 3-
5mm was scored 2 (moderate); and >5mm was scored 3 (severe). 
Furthermore, oviducts were ethanol fixed, sectioned and stained with 
haematoxylin and eosin, then numbers of infiltrating immune cells 
(polymorphonuclear leukocytes and lymphocytes) counted per high power 
field. Data presented are representative of two separate experiments. 
 
Results 
 
Immunization with MOMP and CT/CpG results in high titres of 
neutralising antibodies in VL 
Immunized mice were assessed for levels of VL MOMP-specific antibodies by 
ELISA. MOMP-specific IgA was present at an EPT of ~200 in the mice 
receiving intranasal (IN) immunization with MOMP and CT/CpG+MOMP, and 
also in the group given an intra-vaginal live inoculation (LIC) with C. 
muridarum (Fig.1A). MOMP-specific IgG was seen in both immunized groups 
receiving MOMP, with an EPT of ~150 for IN-MOMP, and ~320 for IN-
CT/CpG+MOMP (Fig.1B). Levels of IgG in the serum were also high in these 
two groups, and these MOMP-specific antibodies (VL and serum) dropped 
significantly from 1-8 weeks post-infection (data not shown).  
 
When the VL sample was obtained from LIC mice, approximately 75% in vitro 
neutralization of C. muridarum infection of McCoy cells was observed. The VL 
from mice immunized with CT/CpG+MOMP demonstrated neutralization of 
approximately 65% (Fig. 2).  Little to no neutralization was seen with VL 
samples collected from immunized mice at 8 weeks post-boost (data not 
shown). The VL samples collected at one-week post-boost were thus selected 
for subsequent investigation. It is interesting to note that although low levels of 
MOMP-specific IgG were present in the VL of LIC mice, these samples 
showed significant neutralization.  
 
Neutralizing MOMP-specific antibodies slightly enhance clearance of C. 
muridarum 
Due to variations in levels of initial infection achieved between mice, the data 
are presented as numbers of mice positive for infection (defined as >10 ifu per 
high power field) every three days post-inoculation up to Day21 (Table 1). 
Mice receiving C. muridarum pre-incubated with VL from all negative control 
groups (No VL, Naïve VL, MOMP only, adjuvants only) showed little 
difference in clearance rates. The mice receiving anti-C. muridarum VL (from 
LIC mice) in conjunction with C. muridarum demonstrated the best clearance, 
which was not unexpected. The VL from CT/CpG+MOMP immunized mice 
which contained high levels of in vitro neutralizing antibodies, was able to 
slightly enhance the clearance of infection in recipient mice. From Days 9-15, 
this group shows fewer mice positive for infection than the negative control 
groups (with the singular exception of the naïve VL group at Day15 only). 
Beyond this point, Th1-mediated processes would be mobilized 10, likely 
abrogating any potential differences effected by the presence of early-
administered antibodies. 
 
MOMP-specific antibody-bound EB administration results in the 
development of accelerated oviduct pathology 
Despite enhancing chlamydial clearance from the vagina, administering VL 
MOMP-specific antibodies and C. muridarum into the vaginal vault of naïve 
mice has actually generated the presence of moderate to severe hydrosalpinx 
22 days post-inoculation. The groups receiving VL from mice with high titres 
of MOMP-specific IgG showed the greatest pathology scores at day 22, 
particularly in the left oviduct (Fig.3). This phenomenon of greater pathology in 
the left oviduct has also been observed previously (Carey A., unpublished 
results). Furthermore, the groups displaying greater oviduct dilation were 
assessed for numbers of infiltrating immune cells. There was a trend for 
higher numbers of polymorphonuclear leukocytes in the mice receiving VL 
from the MOMP+CT/CpG immunized animals, and there was a significantly 
greater number of lymphocytes in these mice (p=0.0159). 
 
Discussion 
 
Intranasal immunization with MOMP has resulted in the generation of MOMP-
specific mucosal IgA and IgG antibodies in genital tract secretions. This is in 
concordance with previous studies demonstrating that IN immunization can 
effectively target immunity to reproductive tracts of both females and males 18-
20. The abundance of these MOMP-specific antibodies did not directly 
correlate with the ability of the VL samples to neutralize chlamydial infection in 
vitro. The VL from challenged mice, despite possessing no MOMP-specific 
IgG, demonstrated the greatest in vitro neutralization. This is likely due to the 
presence of additional antibodies present in the VL sample, which are 
directed against chlamydial antigens other than MOMP, thus not detected by 
this ELISA assay. Another interesting finding is that the VL from mice 
receiving IN immunization with MOMP alone demonstrated high levels of 
MOMP-specific antibodies, but these were not able to neutralize in vitro 
infection of McCoy cells. CpG adjuvant induces signalling via toll-like receptor 
(TLR) 9, while CT enhances B cell activity 21. The presentation of MOMP 
antigen may follow a different pathway when co-administered with these 
adjuvants, thus possibly resulting in the differences in neutralizing capacity of 
VL antibodies seen in this study.  
 
We aimed to determine what effect the in vitro neutralizing antibodies would 
have on the course of a C. muridarum infection in vivo. Thus, VL samples 
were pre-incubated with C. muridarum, which were then administered to the 
vaginal vaults of naïve mice. The groups receiving antibody-bound EBs 
derived from LIC and CT/CpG+MOMP immunized mice, had slightly fewer 
mice positive for infection from Days 9-15 than mice receiving C. muridarum 
with either no VL or non-immune VL. Similarly, in another study, when C. 
trachomatis elementary bodies (EBs) were pre-coated with IgG2b monoclonal 
antibodies and administered intravaginally to C3H/HeJ mice there was a 
reduced infection 22. In our experiment, in vitro and in vivo neutralization 
capacity was closely related. This is not always the case, as another study 
shows a lack of correlation 22.  
 
C. muridarum EBs in complex with IgG antibody are translocated by Fc-
receptors (FcR) into cells more efficiently than EBs alone. In fact, six times 
more mucosal T cells are initiated in wild type mice than in FcR knockout mice 
in the first week of inoculation with C. muridarum immune complexes 23. This 
does not require active replication. By this mechanism, enhanced 
presentation of MOMP antigen to T cells via FcR would explain the reduction 
in early levels of chlamydial infection observed in this model. Further 
investigations are underway to examine this process. This would also explain 
why other studies in T cell deficient mice have shown limited ability of 
antibodies to clear infections 24, if the primary role of antibodies is to enhance 
or accelerate the activation/activity of cell-mediated immunity.  
 
While some protection was afforded at early time points, perhaps the most 
interesting finding from this investigation was that the presence of MOMP-
specific antibodies accelerated the development of oviduct pathology, namely 
hydrosalpinx. While this is normally observed at or beyond 29 days post-
infection 10, 25, we observed development of severe hydrosalpinx at Day 22 
post-infection, which appeared to correlate with levels of MOMP-specific IgG 
in the VL samples. In mice, oviduct occlusion correlates 100% with infertility 
25.  
 
There are a number of possible mechanisms by which this accelerated 
pathology occurred. The first possibility is that inoculation with antibody-bound 
EBs has effectively reduced the chlamydial dose, resulting in reduced immune 
recognition in the lower reproductive tract and an increased ascending 
infection. Similar phenomena have been observed in female mice where 
genital inoculation with a low dose of C. muridarum has resulted in greater 
chlamydial load in the oviducts 9.  
 
A second possibility is that the presence of antibodies actually induces greater 
tissue infection at an earlier time point than C. muridarum alone, or recruits 
complement, ultimately causing tissue damage in an earlier time frame. 
Interestingly, preliminary experiments have indicated that lower levels of 
MOMP-specific antibodies can actually facilitate, rather than neutralize, 
chlamydial uptake in vitro (data not shown), a phenomenon also previously 
demonstrated with antibodies against chlamydial NrdB 26. The implications for 
these findings have great significance for in vivo studies. It would be 
necessary to determine tissue load throughout the course of the infection, with 
a range of IgG:EB ratios to investigate this possibility.  
 
Endogenous IgG is taken up into Chlamydia infected cells and is co-localised 
with the inclusion, seen in early and late stages of chlamydial development 
both in vitro and in human blood smears from infected patients. This requires 
the Fc region of the immunoglobulins 27. However, Moore et al. 23 
demonstrated that FcR I, II and III knockout mice can still develop 
hydrosalpinx, and thus while possibly still involved in increased antigen 
presentation, the FcRs are not the means by which we observe accelerated 
pathology in this model.  
 
A likely candidate is the neonatal Fc receptor (FcRn). FcRn in human and 
murine dendritic cells enhances uptake of immune complexes 28, 29. In a 
recent study, it was found that cytomegalovirus (CMV) virions were 
transcytosed across the placental surface, co-localized with IgG 30. In villus 
explant studies, low avidity antibodies were predictive of congenital infection 
with CMV, while high avidity IgG resulted in internalized nucleocapsids 
without replication, which were then captured by macrophages 30. FcRn 
saturation with the Fc fragment of human IgG resulted in a decrease in CMV 
virion uptake, thus implicating this receptor in CMV-IgG immune complex 
uptake. FcRn is implicated in other inflammatory pathologies including 
rheumatoid arthritis and bullous pemphigoid 31, 32. Simple interfering RNA 
studies are underway to determine if FcRn is involved in the pathology of 
chlamydial infection. There is strong expression of FcRn in the efferent ducts 
and caput epididymis of the male rat, consistent with regions of IgG 
reabsorption from lumen into epithelial cells in these regions 33, and we have 
determined the presence of FcRn in McCoy cells used in these in vitro studies 
(data not shown).   
 
A third possible explanation for antibody-bound EB-mediated acceleration of 
pathology development is an early interaction of intracellular C. muridarum 
and TLR2. Whether rapid ascension of EBs or early uptake into epithelial cells 
occurs, this may result in the early induction of TLR2-signalling events that 
are essential for pathology 12. Interaction of EBs and TLR2 likely occurs at the 
phagosome 34, and downstream signaling requires active replication and the 
presence of the EB plasmid 12, 35. This results in the secretion of TNF- 35 and 
MIP-2 36, and subsequent neutrophil recruitment, therefore this step is 
essential for the development of pathology.  
 
Future studies will examine these hypothesized mechanisms of accelerated 
pathology development observed in this model. This will improve our 
understanding of the pathophysiology of oviduct occlusion in vivo, and 
hopefully provide us with targets to inhibit such pathology in response to 
future vaccination protocols.    
 
Conclusions 
 
The findings of this investigation and future studies have strong implications, 
not only for determining mechanisms of reproductive disease and infertility of 
women, but also for vaccine development. While the vast majority of vaccine 
experiments report on reduction of bacterial shedding, the potential for 
experimental vaccines to induce damaging immunity resulting in organ 
disease is largely ignored, and rarely reported in the literature. The potential 
for immunity to induce pathology must always be considered in rational 
vaccine design. 
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Tables 
 
Table 1: Numbers of mice positive for chlamydial infection (>10ifu per HPF) 
 
Day No VL Naïve LIC MOMP CT/CpG MOMP 
    VL       +CT/CpG 
6 10 10 9 10 10 10 
9 9 9 7 10 10 8 
12 10 7 6 7 8 5 
15 7 5 3 8 7 5 
18 1 3 1 4 2 2 
21 0 0 1 1 0 1 
VL: vaginal lavage, LIC: live inoculation control, MOMP: major outer-membrane protein 
CT/CpG: cholera toxin/CpG oligodeoxynucleotides 
 
 
 
Figure captions 
 
Figure 1.  Vaginal lavage antibodies following intranasal immunization. One 
week post-boost vaginal lavage samples were collected from five mice per 
group, and ELISA conducted to determine levels of MOMP-specific IgA (A)  
and IgG (B). Absorbance at 450nm was measured and end point titre 
determined. Significance (*) denotes a p-value of <0.05 by Student’s t-test 
compared to naïve mice. Data presented are pooled from two separate 
experiments. 
 
Figure 2.  In vitro neutralization of C. muridarum with vaginal lavage samples 
from immunized mice. McCoy cell monolayers were inoculated with 5 x 104 ifu 
C. muridarum pre-incubated with a 1/5 dilution of vaginal lavage. Infection 
proceeded for 24h before cells were fixed, then DAB-stained for inclusion 
counting. Number of inclusion forming units per mL of inoculating fluid were 
determined and t-tests conducted on each sample compared to C. muridarum 
only control for significance (* p<0.05).  
 
Figure 3.  Pathology assessment. Naïve mice were administered antibody-
bound EBs via the vaginal vault. At day 22 post-infection, mice were sacrificed 
and degree of pathology of the oviducts graded (A); no oviduct dilation = 0; 
mild dilation = 1; moderate = 2; severe = 3. Also, tissues were fixed, sectioned 
and H&E stained and assessed for numbers of polymorphonuclear leukocytes 
(B), and lymphocytes (C). Results presented are from five recipient mice per 
group. 
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